Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane

S. M. Maira, I. Galetic, D. P. Brazil, Stefanie Kaech-Petrie, E. Ingley, M. Thelen, B. A. Hemmings

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

The PKB (protein kinase B, also called Akt) family of protein kinases plays a key role in insulin signaling, cellular survival, and transformation. PKB is activated by phosphorylation on residues threonine 308, by the protein kinase PDK1, and Serine 473, by a putative serine 473 kinase. Several protein binding partners for PKB have been identified. Here, we describe a protein partner for PKBα termed CTMP, or carboxyl-terminal modulator protein, that binds specifically to the carboxyl-terminal regulatory domain of PKBα at the plasma membrane. Binding of CTMP reduces the activity of PKBα by inhibiting phosphorylation on serine 473 and threonine 308. Moreover, CTMP expression reverts the phenotype of v-Akt-transformed cells examined under a number of criteria including cell morphology, growth rate, and in vivo tumorigenesis. These findings identify CTMP as a negative regulatory component of the pathway controlling PKB activity.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalScience
Volume294
Issue number5541
DOIs
StatePublished - Oct 12 2001

Fingerprint

Cell Membrane
Protein-Serine-Threonine Kinases
Proteins
Phosphorylation
Proto-Oncogene Proteins c-akt
Threonine
Protein Binding
Protein Kinases
Serine
Carcinogenesis
Insulin
Phenotype
Growth

ASJC Scopus subject areas

  • General

Cite this

Maira, S. M., Galetic, I., Brazil, D. P., Kaech-Petrie, S., Ingley, E., Thelen, M., & Hemmings, B. A. (2001). Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science, 294(5541), 374-380. https://doi.org/10.1126/science.1062030

Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. / Maira, S. M.; Galetic, I.; Brazil, D. P.; Kaech-Petrie, Stefanie; Ingley, E.; Thelen, M.; Hemmings, B. A.

In: Science, Vol. 294, No. 5541, 12.10.2001, p. 374-380.

Research output: Contribution to journalArticle

Maira, SM, Galetic, I, Brazil, DP, Kaech-Petrie, S, Ingley, E, Thelen, M & Hemmings, BA 2001, 'Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane', Science, vol. 294, no. 5541, pp. 374-380. https://doi.org/10.1126/science.1062030
Maira, S. M. ; Galetic, I. ; Brazil, D. P. ; Kaech-Petrie, Stefanie ; Ingley, E. ; Thelen, M. ; Hemmings, B. A. / Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. In: Science. 2001 ; Vol. 294, No. 5541. pp. 374-380.
@article{c72f1bed1c604ff0ab89b34e1a74b457,
title = "Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane",
abstract = "The PKB (protein kinase B, also called Akt) family of protein kinases plays a key role in insulin signaling, cellular survival, and transformation. PKB is activated by phosphorylation on residues threonine 308, by the protein kinase PDK1, and Serine 473, by a putative serine 473 kinase. Several protein binding partners for PKB have been identified. Here, we describe a protein partner for PKBα termed CTMP, or carboxyl-terminal modulator protein, that binds specifically to the carboxyl-terminal regulatory domain of PKBα at the plasma membrane. Binding of CTMP reduces the activity of PKBα by inhibiting phosphorylation on serine 473 and threonine 308. Moreover, CTMP expression reverts the phenotype of v-Akt-transformed cells examined under a number of criteria including cell morphology, growth rate, and in vivo tumorigenesis. These findings identify CTMP as a negative regulatory component of the pathway controlling PKB activity.",
author = "Maira, {S. M.} and I. Galetic and Brazil, {D. P.} and Stefanie Kaech-Petrie and E. Ingley and M. Thelen and Hemmings, {B. A.}",
year = "2001",
month = "10",
day = "12",
doi = "10.1126/science.1062030",
language = "English (US)",
volume = "294",
pages = "374--380",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5541",

}

TY - JOUR

T1 - Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane

AU - Maira, S. M.

AU - Galetic, I.

AU - Brazil, D. P.

AU - Kaech-Petrie, Stefanie

AU - Ingley, E.

AU - Thelen, M.

AU - Hemmings, B. A.

PY - 2001/10/12

Y1 - 2001/10/12

N2 - The PKB (protein kinase B, also called Akt) family of protein kinases plays a key role in insulin signaling, cellular survival, and transformation. PKB is activated by phosphorylation on residues threonine 308, by the protein kinase PDK1, and Serine 473, by a putative serine 473 kinase. Several protein binding partners for PKB have been identified. Here, we describe a protein partner for PKBα termed CTMP, or carboxyl-terminal modulator protein, that binds specifically to the carboxyl-terminal regulatory domain of PKBα at the plasma membrane. Binding of CTMP reduces the activity of PKBα by inhibiting phosphorylation on serine 473 and threonine 308. Moreover, CTMP expression reverts the phenotype of v-Akt-transformed cells examined under a number of criteria including cell morphology, growth rate, and in vivo tumorigenesis. These findings identify CTMP as a negative regulatory component of the pathway controlling PKB activity.

AB - The PKB (protein kinase B, also called Akt) family of protein kinases plays a key role in insulin signaling, cellular survival, and transformation. PKB is activated by phosphorylation on residues threonine 308, by the protein kinase PDK1, and Serine 473, by a putative serine 473 kinase. Several protein binding partners for PKB have been identified. Here, we describe a protein partner for PKBα termed CTMP, or carboxyl-terminal modulator protein, that binds specifically to the carboxyl-terminal regulatory domain of PKBα at the plasma membrane. Binding of CTMP reduces the activity of PKBα by inhibiting phosphorylation on serine 473 and threonine 308. Moreover, CTMP expression reverts the phenotype of v-Akt-transformed cells examined under a number of criteria including cell morphology, growth rate, and in vivo tumorigenesis. These findings identify CTMP as a negative regulatory component of the pathway controlling PKB activity.

UR - http://www.scopus.com/inward/record.url?scp=0035850916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035850916&partnerID=8YFLogxK

U2 - 10.1126/science.1062030

DO - 10.1126/science.1062030

M3 - Article

VL - 294

SP - 374

EP - 380

JO - Science

JF - Science

SN - 0036-8075

IS - 5541

ER -